Sectors & markets
Singapore at the Forefront: Major Breakthroughs in Women’s Cancer Treatment
PHOTO: The Straits Times
Market Info | Health & Lifestyle | Oncology and Biotechnology
Date: 15 April 2026
Region: ASEAN-O
Country: Singapore
Sector: Health & Lifestyle
Sub-sector: Oncology and Biotechnology
Section: Market Trends
Theme: Therapeutic Innovations and Women’s Health
Singapore-based research teams led by the Agency for Science, Technology and Research (A*STAR), in collaboration with the Singapore General Hospital Cancer Centre (SGH) and the National University Cancer Institute, Singapore (NCCS), have announced groundbreaking advancements in the treatment of women-specific cancers, particularly breast and ovarian cancers. Published in early 2026, these studies highlight significant progress in developing targeted therapies and personalized immunotherapeutic approaches, marking a turning point in the management of these diseases.
One of the most promising innovations involves the use of artificial intelligence (AI) and genomic sequencing to analyze the unique molecular profiles of tumors. This method enables the identification of patient-specific biomarkers, paving the way for tailored treatments while reducing the side effects associated with traditional chemotherapy. Clinical trials conducted on a sample of 500 patients demonstrated a 30% improvement in response rates for those with advanced ovarian cancer, as well as a 20% reduction in recurrence for hormone-dependent breast cancers.
These breakthroughs align with Singapore’s national "Healthier SG" strategy, which aims to strengthen prevention, early detection, and access to cutting-edge care for the entire population. Singapore is thus consolidating its position as a regional leader in oncological research, attracting international partnerships and investments in biotechnology. The government has announced an additional €33 million in funding to support these initiatives, underscoring the importance of translational research and medical innovation.
Breast and ovarian cancers remain among the leading causes of morbidity and mortality among women in Singapore, accounting for the first and fifth most diagnosed cancers, respectively, according to the latest data from the Singapore Cancer Registry. These new therapies offer renewed hope for thousands of patients while easing the burden on the healthcare system through more effective and cost-efficient long-term treatments.
